Form 4: Immunic Inc. Director Tamar Howson Reports Stock Option Repricing

Director Tamar Howson reports the repricing of stock options at Immunic, Inc. following stockholder approval.

Summary

• On March 4, 2024, Immunic, Inc.'s stockholders approved a proposal to reduce the exercise price of eligible employee stock options to the greater of $1.72 or 110% of the closing price on a future repricing date.
• The Board of Directors set the repricing date as March 4, 2024, and determined that the exercise price of all eligible options would be repriced to $1.72 per share.
• This Form 4 reflects the cancellation of existing eligible options and the reissuance of those options at the new exercise price of $1.72 per share.
• The repriced options retain their original vesting schedule and expiration date.

Sentiment

Score: 6

Explanation: The document describes a routine administrative action (stock option repricing). It's neither particularly positive nor negative from an investment perspective, but suggests the company is taking steps to maintain employee motivation.

Positives

• The repricing of stock options could incentivize employees and align their interests with those of shareholders.
• The repricing could make the options more valuable to employees, potentially improving morale and retention.

Future Outlook

The repriced options retain their original vesting schedule and expiration date, suggesting a continuation of existing equity compensation plans.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees when the stock price has fallen below the option's exercise price. This is common in the biotech industry, which can be volatile.

Comparison to Industry Standards

• Repricing stock options is a relatively common practice, especially in volatile sectors like biotechnology.
• Many companies, including those in the pharmaceutical and biotech industries, have repriced options during periods of stock price decline to maintain employee motivation.
• Comparing Immunic's repricing to similar actions by companies like BioCryst Pharmaceuticals or Sarepta Therapeutics could provide further context, but specific details of those actions would be needed.

Stakeholder Impact

• The repricing of stock options could positively impact employees by increasing the potential value of their options.
• Shareholders may view the repricing as a positive step to retain and motivate employees, but some may see it as dilutive if the options are eventually exercised.

Key Dates